A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Threat of superbugs looms large with few new...
Media - published on 18 Nov 2021
Share

Threat of superbugs looms large with few new drugs in the pipeline

Anne Gulland covers the 2021 Antimicrobial Resistance Benchmark in The Telegraph.

Explore further

Media

Poorer nations still lack access to world’s key antibiotics

Julia Kollewe covers the 2021 Antimicrobial Resistance Benchmark in The Guardian.
Media

Companies make progress tackling drug-resistant infections, foundation says

Ludwig Burger reports on the 2021 Antimicrobial Resistance Benchmark for Reuters.
Media

Millions Miss Out on Antibiotics in Echo of Vaccine Inequity

James Paton writes for Bloomberg Health about the findings of the 2021 Antimicrobial Resistance Benchmark.

Back to top |